United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - fluticasone furoate; vilanterol - inhalation powder - 184microgram/1dose ; 22microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - vilanterol; fluticasone furoate - inhalation powder - 22microgram/1dose ; 92microgram/1dose

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd - fluticasone (fluticasone furoate), vilanterol - powder for inhalation - 100mcg/dose+ 25mcg/dose

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd - fluticasone (fluticasone furoate), vilanterol - powder for inhalation - 200mcg/dose+ 25mcg/dose

European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - fluticasone furoate, vilanterol - pulmonary disease, chronic obstructive - adrenergics and other drugs for obstructive airway diseases - asthma indication:relvar ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.copd indication:relvar ellipta is indicated for the symptomatic treatment of adults with copd with a fev1

European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - fluticasone furoate, vilanterol trifenatate - asthma - adrenergics and other drugs for obstructive airway diseases - asthma indicationrevinty ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.copd indicationrevinty ellipta is indicated for the symptomatic treatment of adults with copd with a fev1

Canada - English - Health Canada

glaxosmithkline inc - vilanterol (vilanterol trifenatate); fluticasone furoate - powder - 25mcg; 100mcg - vilanterol (vilanterol trifenatate) 25mcg; fluticasone furoate 100mcg - adrenals

Canada - English - Health Canada

glaxosmithkline inc - fluticasone furoate; vilanterol (vilanterol trifenatate) - powder - 200mcg; 25mcg - fluticasone furoate 200mcg; vilanterol (vilanterol trifenatate) 25mcg - adrenals

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - fluticasone furoate; vilanterol - inhalation powder - 184microgram/1dose ; 22microgram/1dose

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - vilanterol; fluticasone furoate - inhalation powder - 22microgram/1dose ; 92microgram/1dose